- Q2 2025 sales were CHF 968 million, flat in local currencies, with a 17.5% EBITDA margin.
- H1 2025 sales reached CHF 1.981 billion, up 1% in local currencies, with an 18.1% EBITDA margin.
- CHF 80 million savings program underway, with CHF 12 million saved in H1 2025.
- 2025 sales growth forecast adjusted to 1-3%, with a confirmed EBITDA margin target of 17-18%.
Financial Performance
In Q2 2025, sales were CHF 968 million, flat in local currencies, with a 17.5% EBITDA margin, up 200 basis points from the previous year. H1 2025 sales increased by 1% in local currencies to CHF 1.981 billion, with an 18.1% EBITDA margin, up 130 basis points.
Regional and Segment Insights
Sales in the Americas rose by 6%, driven by Catalysts projects in the U.S. and Care Chemicals growth in Brazil. Europe, Middle East & Africa saw a 2% decline, while Asia-Pacific sales fell by 3%, with China down 3% despite growth in India.
Cost Management and Savings
The Investor Day savings program targets CHF 80 million by 2027, with CHF 12 million saved in H1 2025. Measures include headcount reductions, site closures, and procurement savings. Restructuring charges of CHF 22 million impacted reported EBITDA.
Outlook and Targets
2025 sales growth forecast is adjusted to 1-3%, with a confirmed EBITDA margin target of 17-18%. Exceptional items, including CHF 75 million in restructuring charges, are expected. Medium-term targets for 2027 include 4-6% sales growth and a 19-21% EBITDA margin.
Innovation and Sustainability
The CLARITY™ digital platform expanded to over 185 customer plants, enhancing catalyst management. Greenhouse gas emissions fell by 10% due to increased renewable electricity use. New 2030 emissions reduction targets were approved by the Science Based Targets Initiative.
